Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
2 "Han-Jo Kim"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Case Report
Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis
Won-Young Park, Han-Jo Kim, Kyoungha Kim, Sang-Byung Bae, Namsu Lee, Kyu-Taek Lee, Jong-Ho Won, Hee-Sook Park, Sang-Cheol Lee
Cancer Res Treat. 2016;48(2):843-847.   Published online March 2, 2015
DOI: https://doi.org/10.4143/crt.2014.234
AbstractAbstract PDFPubReaderePub
Leptomeningeal carcinomatosis is a fatal manifestation of metastatic breast cancer. Investigation of intrathecal (IT) trastuzumab for leptomeningeal carcinomatosis is currently underway; however, there has been no consensus. We report on two cases of human epidermal growth factor receptor 2 positive (HER2+) breast cancer following IT trastuzumab for leptomeningeal carcinomatosis. The first patient was treated with weekly IT 15 mg methotrexate plus IT 50 mg trastuzumab for 7 months, followed by IT trastuzumab (50 mg > 25 mg) for 18 months. The other patient received IT trastuzumab with systemic chemotherapy (trastuzumab and/or paclitaxel) for 13 months. Good control of leptomeningeal disease was achieved with IT trastuzumab in both patients, with survival durations of 20 and 29 months, respectively. We suggest that IT trastuzumab is a promising treatment for patients with HER2+ breast cancer and leptomeningeal carcinomatosis.

Citations

Citations to this article as recorded by  
  • The research progress on meningeal metastasis in solid tumors
    Yi Yue, Yuqing Ren, Chunya Lu, Nan Jiang, Sihui Wang, Junkai Fu, Mengrui Kong, Guojun Zhang
    Discover Oncology.2025;[Epub]     CrossRef
  • An overview of the therapeutic strategies for neoplastic meningitis due to breast cancer: when and why?
    Mainak Bardhan, Debankur Dey, Vinay Suresh, Binish Javed, Vyshak Alva Venur, Neha Joe, Ritvika Kalidindi, Ahmad Ozair, Marium Khan, Reshma Mahtani, Simon Lo, Yazmin Odia, Manmeet S. Ahluwalia
    Expert Review of Neurotherapeutics.2024; 24(1): 77.     CrossRef
  • Intrathecal Trastuzumab for HER2-Positive Cancer of Unknown Primary Leptomeningeal Metastasis: A Case Report
    Kohei Oka, Shun Futamura, Taishi Harada
    Cureus.2024;[Epub]     CrossRef
  • A Review on the Efficacy and Safety of Intrathecal Administration of Novel Medications for Leptomeningeal Metastases in Solid Cancers
    Fatemeh Jafari, Mohammad Moeini Nodeh, Hesamoddin Hosseinjani, Hamed Baharara, Sajad Azad, Omid Arasteh, Thomas P. Johnston, Amirhossein Sahebkar
    Current Medicinal Chemistry.2024; 31(19): 2732.     CrossRef
  • Leptomeningeal Carcinomatosis from Solid Tumor Malignancies: Treatment Strategies and Biomarkers
    Rachna Malani, Ankush Bhatia, Allison Betof Warner, Jonathan T. Yang
    Seminars in Neurology.2023; 43(06): 859.     CrossRef
  • Leptomeningeal metastases: the future is now
    Rimas V. Lukas, Jigisha P. Thakkar, Massimo Cristofanilli, Sunandana Chandra, Jeffrey A. Sosman, Jyoti D. Patel, Priya Kumthekar, Roger Stupp, Maciej S. Lesniak
    Journal of Neuro-Oncology.2022; 156(3): 443.     CrossRef
  • Durable Effect of Pyrotinib and Metronomic Vinorelbine in HER2-Positive Breast Cancer With Leptomeningeal Disease: A Case Report and Literature Review
    Yajing Chi, Mao Shang, Liang Xu, Heyi Gong, Rongjie Tao, Lihua Song, Baoxuan Zhang, Sha Yin, Binbin Cong, Huihui Li
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression
    Flora Zagouri, Panagiotis Zoumpourlis, Emilie Le Rhun, Rupert Bartsch, Eleni Zografos, Kleoniki Apostolidou, Meletios-Athanasios Dimopoulos, Matthias Preusser
    Cancer Treatment Reviews.2020; 88: 102046.     CrossRef
  • Leptomeningeal carcinomatosis in patients with breast cancer
    Maria Alice Franzoi, Gabriel N. Hortobagyi
    Critical Reviews in Oncology/Hematology.2019; 135: 85.     CrossRef
  • Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy
    Nicholas B. Figura, Victoria T. Rizk, Homan Mohammadi, Brittany Evernden, Sepideh Mokhtari, H. Michael Yu, Timothy J. Robinson, Arnold B. Etame, Nam D. Tran, James Liu, Iman Washington, Roberto Diaz, Brian J. Czerniecki, Hatem Soliman, Hyo S. Han, Solmaz
    Breast Cancer Research and Treatment.2019; 175(3): 781.     CrossRef
  • Breast leptomeningeal disease: a review of current practices and updates on management
    Nicholas B. Figura, Victoria T. Rizk, Avan J. Armaghani, John A. Arrington, Arnold B. Etame, Hyo S. Han, Brian J. Czerniecki, Peter A. Forsyth, Kamran A. Ahmed
    Breast Cancer Research and Treatment.2019; 177(2): 277.     CrossRef
  • Medical Management of Brain Metastases and Leptomeningeal Disease in Patients with Breast Carcinoma
    Kelsey M Bowman, Priya Kumthekar
    Future Oncology.2018; 14(4): 391.     CrossRef
  • Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience
    Nicholas B. Figura, Wendy Long, Michael Yu, Timothy J. Robinson, Sepideh Mokhtari, Arnold B. Etame, Nam D. Tran, Roberto Diaz, Hatem Soliman, Heather S. Han, Solmaz Sahebjam, Peter A. Forsyth, Kamran A. Ahmed
    Breast Cancer Research and Treatment.2018; 169(2): 391.     CrossRef
  • Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches
    Niyanta N. Kumar, Michelle E. Pizzo, Geetika Nehra, Brynna Wilken-Resman, Sam Boroumand, Robert G. Thorne
    Bioconjugate Chemistry.2018; 29(12): 3937.     CrossRef
  • Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era
    J. Remon, E. Le Rhun, B. Besse
    Cancer Treatment Reviews.2017; 53: 128.     CrossRef
  • Current challenges in the management of breast cancer brain metastases
    Ciara C. O’Sullivan, Nicole N. Davarpanah, Jame Abraham, Susan E. Bates
    Seminars in Oncology.2017; 44(2): 85.     CrossRef
  • Leptomeningeal disease: current diagnostic and therapeutic strategies
    Gautam Nayar, Tiffany Ejikeme, Pakawat Chongsathidkiet, Aladine A. Elsamadicy, Kimberly L. Blackwell, Jeffrey M. Clarke, Shivanand P. Lad, Peter E. Fecci
    Oncotarget.2017; 8(42): 73312.     CrossRef
  • Leptomeningeal metastases of solid cancer
    Emilie Le Rhun, Evanthia Galanis
    Current Opinion in Neurology.2016; 29(6): 797.     CrossRef
  • Metastatic breast cancer: The Odyssey of personalization
    A. Sonnenblick, N. Pondé, M. Piccart
    Molecular Oncology.2016; 10(8): 1147.     CrossRef
  • Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?
    Eleonora Teplinsky, Francisco J. Esteva
    Current Oncology Reports.2015;[Epub]     CrossRef
  • 16,585 View
  • 193 Download
  • 21 Web of Science
  • 20 Crossref
Close layer
Original Article
A Phase II Study of Irinotecan, 5-Fluorouracil and Leucovorin for Treatment in Patients with Previously Untreated Advanced Colorectal Cancer
Sang-Byung Bae, Nam-Su Lee, Han-Jo Kim, Kyoung-Ha Kim, Hyun-Jung Kim, Chan-Kyu Kim, Kyu-Taeg Lee, Sung-Kyu Park, Jong-Ho Won, Dae-Sik Hong, Hee-Sook Park
Cancer Res Treat. 2006;38(2):72-77.   Published online April 30, 2006
DOI: https://doi.org/10.4143/crt.2006.38.2.72
AbstractAbstract PDFPubReaderePub
Purpose

We prospectively conducted a non-randomized phase II trial to evaluate the efficacy and safety of combination irinotecan, leucovorin (LV) and 5-fluorouracil (FU) as a first-line regimen for treating patients with previously untreated advanced colorectal cancer (CRC).

Materials and Methods

Twenty-six previously untreated patients with advanced, recurrent or metastatic CRC were enrolled in this study. The patients received either irinotecan 180 mg/m2 on day 1 with LV bolus of 200 mg/m2 and FU bolus of 400 mg/m2, and this was followed by FU continuous infusion of 600 mg/m2 on day 1 and day 2 (the FOLFIRI regimen), or they were treated with LV bolus of 400 mg/m2 and FU bolus of 400 mg/m2 followed by FU continuous infusion of 2,400 mg/m2 for 46 hours (the simplified FOLFIRI regimen), and these treatments were repeated every 2 weeks until disease progression.

Results

The objective response rate was 23.1% (6/26) respectively, for both treatments. The median time to progression was 5.3 months (range: 0.4~19.9), and the overall survival was 11.2 months (range: 0.5~52.3). The prognostic factor for longer survival was the Eastern Cooperative Oncology Group (ECOG) performance status (PS). The non-hematological toxicities were similar for both treatment groups, with more frequent grade ≥3 neutropenia being noted for the simplified FOLFIRI regimen.

Conclusion

The biweekly irinotecan based regimen was demonstrated to have a moderate antitumor activity with acceptable toxicity profiles, and the ECOG PS was the independent prognostic factor.

Citations

Citations to this article as recorded by  
  • Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review
    Louise André, Gabriel Antherieu, Amélie Boinet, Judith Bret, Thomas Gilbert, Rabia Boulahssass, Claire Falandry
    Cancers.2022; 14(10): 2470.     CrossRef
  • The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab
    B. Budai, T. Nagy, I. Láng, E. Hitre
    Angiogenesis.2013; 16(1): 113.     CrossRef
  • Successful Treatment of Small-Cell Lung Cancer With Irinotecan in a Hemodialysis Patient With End-Stage Renal Disease
    Dong Min Kim, Hyun Lee Kim, Choon Hae Chung, Chi Young Park
    The Korean journal of internal medicine.2009; 24(1): 73.     CrossRef
  • 12,100 View
  • 68 Download
  • 3 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP